Phase I/II Trial of Ibrutinib, Dexamethasone, and Lenalidomide as Initial Therapy for Transplant Ineligible Multiple Myeloma Patients
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Dexamethasone (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2017 Planned End Date changed from 1 Feb 2022 to 15 Feb 2022.
- 29 Nov 2017 Planned primary completion date changed from 1 Feb 2022 to 15 Feb 2022.
- 14 Mar 2017 Status changed from not yet recruiting to recruiting.